MedTrace Logo

Continuous Glucose Monitoring (CGM) After Kidney Transplantation

NCT06675903 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2024-11-13

No results posted yet for this study

Summary

This study examines glucose levels measured by continuous glucose monitoring (CGM) in the immediate period following kidney transplantation among recipients with diabetes, without diabetes, and with pre-diabetes.

The primary objective is to analyse differences in mean sensor glucose between these three groups.

CGMs are applied to participants within 72 hours after kidney transplantation, with a total of 54 participants divided equally across the three groups (18 in each).

Secondary objectives include assessing additional glucose profile indices, adherence to relevant guidelines, changes in HbA1c, the impact of immunosuppression and steroid dosage, and beta cell function.

Conditions

  • Hyperglycaemia
  • Kidney Transplantation

Sponsors & Collaborators

  • Bo Feldt-Rasmussen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-12
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06675903 on ClinicalTrials.gov